Group 1: Macroeconomic Overview - The US dollar index continued to rise, deepening the "inverted" interest rate differential between China and the US, with both nominal and real yields on 10-year US Treasuries increasing, indicating a rise in inflation expectations [1][13][18] - Domestic interbank liquidity remains generally balanced and loose, with the yield curve steepening as the 10Y-1Y spread widens [1][22][28] Group 2: Market Trading Activity - Overall market trading activity has rebounded, with trading heat in sectors such as textiles, light industry, retail, machinery, and military exceeding the 90th percentile, while volatility has decreased across major indices [2][30][31] - The liquidity indicators in the market have continued to decline, particularly in the coal and banking sectors, which remain above the 60th historical percentile [2][38][41] Group 3: Sector Research and Analyst Predictions - Research interest is high in sectors such as electronics, pharmaceuticals, home appliances, food and beverage, computers, and machinery, with rising interest in non-ferrous metals, consumer services, textiles, real estate, retail, and electric power [3][45][46] - Analysts have continued to lower net profit forecasts for the entire A-share market for 2025/2026, while sectors like transportation, banking, building materials, and home appliances have seen upward revisions in their profit forecasts [2][52] Group 4: Northbound Capital Activity - Northbound capital activity has increased, with net purchases primarily in sectors such as telecommunications, electronics, electric power, utilities, machinery, and new energy, while net sales were observed in pharmaceuticals, computers, and media [3][5] - The average daily trading volume of northbound capital has risen, although its proportion of total A-share trading has decreased [3][5] Group 5: Margin Financing and Fund Activity - Margin financing activity has reached its highest point since late March 2025, with net purchases concentrated in TMT, machinery, military, pharmaceuticals, and automotive sectors, while net sales were seen in banking, transportation, food and beverage, new energy, and textiles [4][6] - Active equity funds have increased their positions, particularly in food and beverage, pharmaceuticals, transportation, electric power, financial real estate, and consumer services, while reducing exposure to new energy, machinery, telecommunications, agriculture, and military sectors [5][12]

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential investment opportunities as the sector stabilizes [20]. 4. Blood Products - The report highlights the demand for immunoglobulin products and the potential for price increases due to supply shortages, recommending companies with strong product lines in this area [22]. 5. Vaccine Sector - The vaccine sector is currently under pressure, but there are opportunities in specific products that may gain market share, particularly in HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and operational capabilities in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drug growth [37]. 9. Medical Services - Investment opportunities are identified in ophthalmology and dental services, with a focus on companies that can leverage consumer healthcare trends [42]. 10. Pharmacy Sector - The report indicates that leading pharmacy chains are stabilizing, and suggests focusing on companies with strong supply chain capabilities [45]. 11. Raw Materials - The raw materials sector is undergoing significant changes due to procurement policies, with recommendations for companies that can adapt to these shifts [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in medical devices and the ongoing trend of domestic replacements in various medical fields [51]. 13. Instrument Equipment - The scientific instrument sector is expected to recover as demand increases, with a focus on companies that are expanding their product offerings [56]. 14. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies that can capitalize on emerging market trends [59].

Group 1 - The deep value investment philosophy is derived from Graham's "cigar butt" approach, focusing on stocks priced significantly below their liquidation value, particularly during economic downturns [8][10] - The deep value fund pool has demonstrated stable historical returns, with an annualized return of 11.05% from February 2, 2015, to May 8, 2025, outperforming the equity fund index by 4.54% [10][13] - The fund pool exhibits a high-risk return ratio, with an annualized volatility of 20.46% and a Sharpe ratio of 0.54, indicating strong return stability [10][13] Group 2 - The excess returns of the fund pool are primarily attributed to dynamic allocation, style configuration, and stock selection, favoring low momentum, low elasticity, and low volatility styles [2][13] - The current portfolio has shifted towards increased allocation in the consumer sector while maintaining exposure to manufacturing and TMT sectors [21][22] - The deep value fund pool is defined by absolute undervaluation characteristics, with a focus on funds that have positive exposure to the BP factor and high expected net profit [24][25] Group 3 - The current deep value fund list includes several funds with varying scales and returns, such as Guangfa Stable Strategy with a scale of 2.39 billion and a return of 4.55% [25] - The fund pool's historical performance shows resilience even during market style shifts, maintaining positive absolute returns despite some drawdowns [13][21] - The fund pool's industry allocation has primarily been in financial and cyclical sectors, with recent adjustments to increase consumer sector exposure [21][22]

基金分析报告 景气价值基金池 202505：科技制造为主 2025 年 05 月 12 日 ➢ 注重公司以及所处赛道的成长性并兼顾估值水平。以彼得·林奇为代表的景 气价值投资策略，更注重公司以及所处赛道的成长性并兼顾估值水平，因而也属 于价值投资范畴，这一投资理念对内在价值的审美更多在于增长潜力而非竞争优 势，景气价值公司的成长未必来源于竞争优势，也可为行业赛道的扩张。本报告 将优选市场当前的景气价值基金，以供对其有配置需求的投资者参考。 ➢ 景气价值型基金池：具备更高的弹性。2015 年 2 月 2 日至 2025 年 5 月 8 日，基金池年化收益率为 8.92%，相对于偏股基金指数超额收益为 2.41%，组合 年化波动为 26.95%。基金池在景气投资表现较好的区间具备比偏股基金指数更 高的收益弹性。 ➢ 超额收益主要源自行业配置，风格更偏成长。景气价值型基金池超额主要来 自于行业配置、动态和选股，其中行业配置的贡献更为明显。风格偏向高流动性、 高动量、高弹性、偏中盘，价值属性整体较弱，更偏成长。当前行业上以 TMT 为 主，更加注重行业的成长性，但 2021 年中到 2022 年底则明显增配了周期赛道 ...

Group 1 - The core investment strategy focuses on buying companies with competitive advantages at reasonable prices to earn compounded growth, emphasizing strong business models and financial robustness [1][8] - The growth value fund pool has shown a stable annualized return of 15.74% from February 2, 2015, to May 8, 2025, outperforming the equity fund index by 9.23% [9][13] - The fund pool's annualized volatility is 20.98%, with a Sharpe ratio of 0.75, indicating strong performance in bull markets and effective drawdown control in bear markets [9][13] Group 2 - The primary source of excess returns is stock selection, with significant contributions from industry allocation and dynamic adjustments [2][13] - The growth value fund pool is defined by its relative undervaluation characteristics, focusing on funds with positive exposure to the PB-ROE factor [21] - Selected funds exhibit high and stable dynamic returns, with a focus on industry and stock selection [22] Group 3 - The report lists a new growth value fund portfolio, highlighting funds such as "Guangfa Value Core A" with a return of 27.79% and "Invesco Financial Industry A" with a return of 5.32% [3][22] - The fund pool has increased its allocation to the TMT sector while reducing exposure to consumer and cyclical sectors [18][15] - The report emphasizes the importance of matching individual company performance with industry trends for effective stock selection [25]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the next 12 months [3][5]. Core Views - The company is expected to experience significant growth in gold production following the completion of its expansion project, with an anticipated annual output of 12.9 tons, representing a 514.3% increase from 2.1 tons in 2024 [2][3]. - The partnership with Zijin Mining is expected to enhance the development speed and efficiency of the company's gold mining operations, particularly at the Jinling Gold Mine [2][3]. - The report projects substantial increases in revenue and net profit from 2025 to 2027, with net profits estimated at 1.26 billion, 1.59 billion, and 1.95 billion RMB respectively [4][6]. Summary by Sections Investment Highlights - The company has entered into significant contracts for mining technology services and feasibility studies for expansion, with a total contract value of 1.69 million RMB for the Jinling Mine [1]. - Zijin Mining's acquisition of a 17.57% stake in the company through a share issuance of 1.66 billion shares at 8.33 HKD per share, totaling 1.379 billion HKD, will fund the expansion and operational costs [2]. Financial Projections - Revenue is projected to grow from 1.88 billion RMB in 2024 to 4.89 billion RMB in 2027, with a compound annual growth rate (CAGR) of 42.6% [4][6]. - The company's earnings per share (EPS) are expected to rise from 0.53 RMB in 2024 to 1.80 RMB in 2027, reflecting strong profitability growth [4][6]. Valuation Metrics - The report provides a price-to-earnings (P/E) ratio forecast of 19X for 2025, 15X for 2026, and 12X for 2027, indicating an attractive valuation as earnings grow [4][6]. - The price-to-book (P/B) ratio is expected to decrease from 7.6 in 2024 to 3.7 in 2027, suggesting improved shareholder value over time [4][6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance in the coming year [3][5]. Core Views - The company is expected to experience significant growth in gold production following the completion of its expansion project, with an anticipated annual output of 12.9 tons, representing a 514.3% increase from 2.1 tons in 2024 [2][3]. - The partnership with Zijin Mining is expected to enhance the development speed and efficiency of the company's gold mining operations, particularly at the Jinling Gold Mine [2][3]. - The report highlights the company's strong financial performance, projecting net profits of 1.26 billion, 1.59 billion, and 1.95 billion RMB for the years 2025, 2026, and 2027 respectively, with corresponding EPS of 1.17, 1.47, and 1.80 RMB [3][4]. Summary by Sections Company Overview - The company has entered into significant contracts for mining technology services and feasibility studies for expansion, with a total contract value of 1.69 million RMB for the Jinling Mine [1]. - Zijin Mining holds a 17.57% stake in the company, which is expected to facilitate the expansion of the Jinling Gold Mine [2]. Financial Projections - Revenue is projected to grow from 1.88 billion RMB in 2024 to 4.89 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 42.6% [4][6]. - The company's net profit is expected to increase significantly, with a growth rate of 119.5% in 2025 and 26.2% in 2026 [4][6]. Valuation Metrics - The report provides a valuation based on projected earnings, with P/E ratios decreasing from 41 in 2024 to 12 in 2027, indicating improving profitability and valuation attractiveness over time [4][6].

可转债周报 20250511 关注弱资质转债风险 2025 年 05 月 11 日 ➢ 转债周度专题 当前转债整体价格及估值已基本修复至关税事件冲击以前。历史来看，自 4 月中下旬开始随着年报逐渐披露，弱资质转债下跌风险逐步攀升，易进一步引发 低信用评级转债整体下调风险，当前仍需关注弱资质转债信用风险。 2024 年 4 月"国九条"出台，对上市公司分红及退市规则等有所调整，今 年开始新规正式实施。分红不达标风险警示方面，结合财务数据来看，当前主板、 科创/创业板转债主体均不存在分红不达标被实施风险警示、退市风险，且转债 主体三年累计分红占归母净利比均值今年显著提升。 退市风险中，财务类退市指标看，2024 年财务数据显示转债主体利润、营 收指标亦均高于新规下退市标准，无直接退市风险，但部分转债主体 2024 年业 绩明显偏弱，未来年度若业绩进一步恶化或面临一定退市风险。 2024 年年报审计意见为非标准无保留意见转债一共 4 只，相比 2023 年的 11 只明显减少。当前 10 只转债最新信用评级被下调/评级展望为负面（2024 同 期为 21 只）。 当前转债整体潜在信用、退市风险或较 2024 年有所 ...

Investment Rating - The report maintains a "Recommended" rating for companies such as China Nuclear Power, Funiu Co., and Huaneng Hydropower, while giving a "Cautious Recommendation" to companies like China General Nuclear Power and Longyuan Power [23][3]. Core Insights - The electricity sector outperformed the market this week, with the public utility sector rising by 2.22% and the electricity sub-sector by 2.21%, both exceeding the Shanghai and Shenzhen 300 index [1][7]. - Shandong Province has established a mechanism electricity price that aligns with the benchmark price for coal-fired power, which is expected to stabilize investment returns for renewable energy projects [2][24]. - The report highlights the significant drop in coal prices, which has led to steady growth in thermal power performance in Q1, with expectations for continued improvement as the peak electricity consumption season approaches [3][20]. Summary by Sections Weekly Market Review - The public utility sector index closed at 2,377.21 points, up 51.64 points, while the electricity sub-sector closed at 3,171.91 points, up 68.52 points [1][7]. - The sub-sectors showed varied performance, with solar power up 4.01%, thermal power up 4.00%, and wind power up 1.78% [12][19]. Special Topic - Shandong's new pricing mechanism for renewable energy projects is set at 0.3949 yuan per kWh, matching the coal-fired benchmark price, which is expected to mitigate revenue volatility for existing projects [2][24]. - The competitive bidding for new renewable projects starting from June 1, 2025, will determine the mechanism price, enhancing investment predictability [2][24]. Investment Recommendations - The report suggests focusing on companies with strong growth potential in the thermal and hydropower sectors, particularly Funiu Co., Gansu Energy, and Huaneng International [3][20]. - It also emphasizes the stability of large hydropower companies in a declining interest rate environment, recommending companies like Yangtze Power and Chuanwei Energy [3][20]. Key Company Earnings Forecasts - The report provides earnings per share (EPS) forecasts for several companies, with China Nuclear Power expected to have an EPS of 0.46 yuan in 2024, while Funiu Co. is projected at 1.07 yuan [23][3].